'Single-cell multiomics of myeloma treated with BCMA-targeted #CARTcells#Immunology#Immunotherapy
Despite the promise of chimeric antigen receptor (CAR) T cell therapy, predicting patient response is challenging. Single-cell multiomics of myeloma treated with B cell maturation antigen (BCMA)-targe...
'Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce' #Immunotherapy#Immunology#CARTcellswww.fiercebiotech.com/biotech/cari...
A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there wer | ...
'Although the information provided by the FDA was thin at the time, the agency told reporters that it had observed 20 cases in which immune-cell cancers known as lymphomas had developed in people treated with CAR T cells.' #Immunology#Immunotherapy#CARTcellswww.nature.com/articles/d41...
Regulators have identified around 30 cases of cancer linked to this blockbuster treatment. But is CAR T to blame? The hunt is on for answers. Regulators have identified around 30 cases of cancer linke...
Another phase I clinical trial demonstrating the safety and efficay of #CARTCellswww.nature.com/articles/s43...
Positive results from a phase I study using @Gilead's anti-MAGE3 and MAGE6 #CARTCellswww.pharmaceutical-technology.com/data-insight...
'Caring Cross has developed a point-of-care manufacturing process able to generate CAR-T therapies for an even lower cost—roughly $20,000 in materials and $10,000 in labor and facilities.' #Immunology#Immunotherapy#CARTcellswww.technologyreview.com/2024/04/12/1...
CAR-T cells could revolutionize the treatment of a wide variety of diseases, if only we can make them cheaper.
